CME Self-Test

CME Self-Test 1. A significant prolongation of survival compared with single-agent gemcitabine was observed in a phase III trial in pancreatic cancer of gemcitabine in combination with: A. Oxaliplatin B. Thalidomide C. Erlotinib D. All of the above 2. Gemcitabine combined with which agent has not shown improved survival in pancreatic cancer over gemcitabine alone: A. 5-FU B. Irinotecan C. Cisplatin D. All of the above 3. Recent trials in ovarian cancer have established improved progression-free survival with the combinations of paclitaxel/platinum and gemcitabine/carboplatin compared with: A. Single-agent paclitaxel in previously untreated patients B. Single-agent platinum in platinum-sensitive recurrent disease C. Sequential paclitaxel and platinum therapy in platinum-sensitive recurrent disease D. None of the above 4. Compared with paclitaxel/platinum, gemcitabine/carboplatin in the treatment of ovarian cancer appears to be associated with lower frequencies of: A. Neurologic toxicity B. Alopecia C. Both of the above D. None of the above 5. Gemcitabine/paclitaxel has shown high activity in which types of breast cancer patients: A. Chemotherapy-naı¨ve patients with metastatic disease B. Pretreated patients with metastatic disease C. Anthracycline-pretreated patients with metastatic disease D. All of the above 6. What was not one of the findings in the phase III JHQG trial in breast cancer comparing gemcitabine/ paclitaxel and single-agent paclitaxel: A. Significantly greater response rate with the combination B. Significantly increased time to disease progression with the combination C. Significantly improved quality of life with single-agent therapy D. None of the above 7. Recent phase III trials have established that which of the following treatments is associated with significantly improved overall survival compared with gemcitabine alone in advanced pancreatic cancer: A. Exatecan plus gemcitabine B. Pemetrexed plus gemcitabine C. Oxaliplatin plus gemcitabine D. None of the above 8. A potentially confounding factor in interpreting results of the GERCOR/GISCAD trial of gemcitabine/oxaliplatin in pancreatic cancer is the use of: A. Standard infusion gemcitabine in the combination arm B. Fixed dose rate infusion of oxaliplatin in the combination arm C. Fixed dose rate infusion of gemcitabine in the combination arm D. Standard infusion of oxaliplatin in the combination arm 6. C

5. D

2. D

Answer key: 1. C

7. D 3. B

8. C 4. C

Seminars in Oncology, Vol 32, No 4, Suppl 6 (August), 2005: p S23

S23